ArticleAnnals of surgical oncology2026
Survival of Open Versus Thoracoscopic Esophagectomy for Esophageal Squamous Cell Cancer by Tumor Location: An Energy Balancing Weights Analysis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe survival impact of open esophagectomy (OE) versus thoracoscopic esophagectomy (TE) in patients with esophageal squamous cell carcinoma (ESCC) based on tumor location remains debated. This study employs energy balancing weights (EBW) to compare long-term survival between OE and TE across tumor locations. PATIENTS AND
methodsThis ambispective cohort study analyzed 1778 patients with ESCC undergoing OE or TE at a tertiary hospital between January 2015 and December 2016. Primary endpoints were 5-year overall survival (OS) and disease-free survival (DFS); secondary endpoints included operative safety. EBW-adjusted Cox regression was used to compare long-term survival, with sensitivity analyses via inverse probability of treatment weighting and matching weight methods.
resultsThe median survival times for upper, middle, and lower tumor locations were 60.06, 60.48, and 64.35 months, respectively. Compared with OE, the Cox regression analysis of TE showed that in the upper group, the HR was 0.45 (95% CI 0.27-0.75) for OS and the HR was 0.55 (0.34-0.89) for DFS. In the middle group, theHR was 0.64 (0.48-0.85) for OS and the HR was 0.70 (0.53-0.91) for DFS. And in the lower group, the HR was 0.70 (0.44-1.11) for OS and the HR was 0.67 (0.43-1.04) for DFS. Additionally, TE was associated with reduced blood loss and increased lymph node yield but had longer operative times and higher costs (P < 0.05).
conclusionsTE improved survival and safety in upper/middle ESCC, while lower tumor locations require individualized approaches. EBW enhanced confounder control, supporting reliable clinical decisions.
Indexed as
Identifiers
41109875What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.